2 weeks Ago By Defense World Staff
Geode Capital Management LLC lessened its stake in shares of Evolent Health, Inc. ( NYSE:EVH – Free Report ) by 0.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission.
The firm owned 2,513,893 shares of the technology company’s stock after selling 6,925 shares during the period. Geode Capital Management LLC owned about 2.16% of Evolent Health worth $28,288,000 at the end of the most recent reporting period.
Other institutional investors have also made changes to their positions in the company. Salem Investment Counselors Inc. grew its position in Evolent Health by 53.
0% during the 4th quarter. Salem Investment Counselors Inc. now owns 350,155 shares of the technology company’s stock worth $3,939,000 after purchasing an additional 121,369 shares in the last quarter.
Nordea Investment Management AB increased its position in Evolent Health by 7.0% in the 4th quarter. Nordea Investment Management AB now owns 130,453 shares of the technology company’s stock worth $1,469,000 after purchasing an additional 8,552 shares during the last quarter.
Harbor Capital Advisors Inc. raised its stake in shares of Evolent Health by 90.1% during the 4th quarter.
Harbor Capital Advisors Inc. now owns 803,211 shares of the technology company’s stock worth $9,036,000 after purchasing an additional 380,790 shares in the last quarter. Franklin Resources Inc.
raised its holdings in shares of Evolent Health by 40.8% during the 3rd quarter. Franklin Resources Inc.
now owns 909,776 shares of the technology company’s stock valued at $24,682,000 after purchasing an additional 263,815 shares in the last quarter. Finally, Barclays PLC lifted its position in shares of Evolent Health by 181.3% in the third quarter.
Barclays PLC now owns 273,776 shares of the technology company’s stock worth $7,742,000 after buying an additional 176,445 shares during the last quarter. Wall Street Analyst Weigh In A number of research analysts recently issued reports on the stock. Piper Sandler reiterated an “overweight” rating and issued a $16.
00 target price (down from $17.00) on shares of Evolent Health in a research note on Friday, February 21st. JPMorgan Chase & Co.
reduced their price objective on Evolent Health from $13.00 to $12.00 and set an “overweight” rating for the company in a research report on Monday, March 10th.
Royal Bank of Canada decreased their target price on Evolent Health from $20.00 to $17.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 14th.
Stephens lowered their price target on Evolent Health from $16.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Tuesday, January 21st.
Finally, Canaccord Genuity Group lowered their price objective on Evolent Health from $23.00 to $16.00 and set a “buy” rating on the stock in a research report on Thursday, January 23rd.
One analyst has rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Evolent Health presently has an average rating of “Buy” and an average target price of $17.64.
Evolent Health Stock Down 3.0 % Shares of NYSE EVH opened at $8.95 on Friday.
The stock has a market cap of $1.04 billion, a PE ratio of -10.92 and a beta of 1.
20. Evolent Health, Inc. has a 52-week low of $8.
35 and a 52-week high of $33.63. The company has a debt-to-equity ratio of 0.
58, a quick ratio of 1.04 and a current ratio of 1.04.
The business has a fifty day moving average of $9.66 and a two-hundred day moving average of $13.41.
Evolent Health ( NYSE:EVH – Get Free Report ) last posted its earnings results on Thursday, February 20th. The technology company reported $0.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.
38 by ($0.35). The firm had revenue of $646.
54 million during the quarter, compared to the consensus estimate of $650.92 million. Evolent Health had a negative net margin of 2.
41% and a positive return on equity of 5.73%. As a group, equities research analysts expect that Evolent Health, Inc.
will post 0.08 earnings per share for the current fiscal year. Insiders Place Their Bets In other Evolent Health news, Director Diane Holder bought 2,735 shares of the business’s stock in a transaction on Thursday, March 6th.
The shares were bought at an average cost of $9.33 per share, for a total transaction of $25,517.55.
Following the transaction, the director now owns 70,584 shares in the company, valued at approximately $658,548.72. This trade represents a 4.
03 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link . Also, President Daniel Joseph Mccarthy acquired 11,040 shares of the firm’s stock in a transaction that occurred on Thursday, March 6th.
The shares were bought at an average cost of $9.01 per share, with a total value of $99,470.40.
Following the completion of the purchase, the president now owns 389,004 shares of the company’s stock, valued at $3,504,926.04. This trade represents a 2.
92 % increase in their ownership of the stock. The disclosure for this purchase can be found here . Insiders have purchased a total of 74,000 shares of company stock valued at $666,315 in the last 90 days.
1.60% of the stock is currently owned by insiders. About Evolent Health ( Free Report ) Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States.
The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients. See Also Five stocks we like better than Evolent Health Earnings Per Share Calculator: How to Calculate EPS Tariff Exemptions Set the Stage for a Taiwan Semiconductor Rally What is the Euro STOXX 50 Index? Mitigating Tariffs: 3 Stocks to Gain From a Weaker U.
S. Dollar Top Biotech Stocks: Exploring Innovation Opportunities Broadcom’s Apple Relationship: AI Opportunity Meets Tariff Risk Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter .
.
